Sol Gel Technolg Stock Price, News & Analysis

Sol-Gel Technologies (NASDAQ: SLGL) announced a 10-for-1 reverse share split effective May 2, 2025, at 11:59 p.m. Eastern Time. The primary goal is to increase share price to regain compliance with Nasdaq's minimum bid price requirement. Trading under the same symbol "SLGL" on the post-split basis will begin May 5, 2025. The consolidation will combine every 10 existing shares into 1 new share, with fractional shares rounded to the nearest whole share. The company's share capital will be adjusted from 50,000,000 to 5,000,000 Ordinary Shares, and the par value will change from 0.1 NIS to 1.0 NIS per share. Proportionate adjustments will be made to outstanding options and warrants.

Sol-Gel Technologies (NASDAQ: SLGL) has entered into a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO. The deal will provide Sol-Gel with $16 million in two installments during 2025, extending their cash runway into Q1 2027.

The company will focus on developing SGT-610, a potential first-ever preventative treatment for basal cell carcinomas in Gorlin syndrome patients, with an estimated U.S. market potential of $400-500 million annually. The Phase III trial has achieved 80% patient enrollment, with top-line results expected in Q4 2026.

As of March 31, 2025, Sol-Gel reported $16.9 million in cash and equivalents. The company is also advancing SGT-210, a treatment for Darier disease with a market potential of $200-300 million, with 50% of patients having completed the Phase 1b trial.

Sol-Gel Technologies (NASDAQ: SLGL) has received a 180-day extension until May 19, 2025, to regain compliance with Nasdaq's minimum bid price requirement. The company has transferred from Nasdaq Global Market to Nasdaq Capital Market effective November 15, 2024. To maintain listing, Sol-Gel must achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. The company is considering various options, including a potential reverse share split, to meet this requirement.

Sol-Gel Technologies (NASDAQ: SLGL) reported Q3 2024 financial results with total revenue of $5.4 million, primarily from licensing agreements, compared to $0.2 million in Q3 2023. The company reported a net loss of $0.4 million ($0.01 per share), improved from a $5.7 million loss in Q3 2023. Cash position stands at $29.2 million, expected to fund operations into Q1 2026.

Key developments include Mori Arkin's approval as interim CEO starting January 2025, transfer to Nasdaq Capital Market, and ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome with 40+ active clinical sites. New licensing agreements for TWYNEO and EPSOLAY are expected to generate up to $3.7 million in milestone payments.

Sol-Gel Technologies (NASDAQ: SLGL) reported Q2 2024 financial results and provided corporate updates. Key highlights include:

- Cash runway extended into Q1 2026
- Ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome with top-line results expected by Q2 2026
- Proof-of-concept study for SGT-210 in Darier disease ongoing
- New agreement with Padagis for generic Zoryve® Cream, enhancing cash position by ~$6 million
- License agreements signed for TWYNEO and EPSOLAY in Europe and South Africa
- Q2 2024 revenue: $5.4 million; Net income: $1.9 million ($0.07 per share)
- Cash balance: $30.5 million as of June 30, 2024

Sol-Gel Technologies (NASDAQ: SLGL) has signed six exclusive license agreements for the commercialization of TWYNEO® and EPSOLAY® in Europe and South Africa. The company will receive upfront and regulatory milestone payments totaling up to low 7-digit USD, along with either fixed transfer sale prices or low double-digit royalties from net sales. These payments are backed by commitments to minimum annual sales.

The agreements cover major European countries, including Germany, UK, France, and others, as well as South Africa. Sol-Gel's partners will be responsible for regulatory submissions, with Sol-Gel providing assistance. These new collaborations add to existing agreements in the US, Canada, and China, highlighting the commercial potential of both drugs.

Sol-Gel is also conducting a Phase 3 trial of SGT-610 for Gorlin syndrome and a clinical study of SGT-210 for Darier disease, aiming to strengthen its business position further.

Sol-Gel Technologies (NASDAQ: SLGL) announced significant management changes. CEO Dr. Alon Seri-Levy will step down from his position and board membership by December 31, 2024, subject to shareholder approval. He will continue as a consultant for one year. Eyal Ben-Or, previously Director of Finance, has been appointed as the new Chief Financial Officer (CFO) effective July 12, 2024, replacing Gilad Mamlok.

Under Dr. Seri-Levy's leadership, Sol-Gel developed FDA-approved products EPSOLAY® and TWYNEO®, completed a successful U.S. IPO, and acquired SGT-610 related assets. The company is currently conducting a Phase 3 clinical trial of SGT-610 for Gorlin syndrome. Chairman Mori Arkin expressed gratitude for Dr. Seri-Levy's contributions and confidence in Ben-Or's appointment.

Sol-Gel Technologies announced on May 28, 2024, receiving a notification from Nasdaq regarding non-compliance with the minimum bid price rule of $1 per share. The company’s shares have traded below $1 for 33 consecutive business days, triggering this notice. This notice does not affect the current listing, and shares will continue trading under the symbol SLGL. Sol-Gel has 180 days, until November 18, 2024, to regain compliance. If the share price reaches $1 for 10 consecutive days before the deadline, compliance will be restored. Sol-Gel is evaluating options to address this issue.

Sol-Gel Technologies (NASDAQ: SLGL) announced its Q1 2024 financial results and corporate updates. Key highlights include an ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome and a proof-of-concept study for SGT-210 in Darier disease. The company entered an Asset Purchase Agreement with Beimei Pharma to commercialize TWYNEO® in several regions, potentially earning up to $15M. Financially, Q1 revenue was $0.5M, up from $0.3M in Q1 2023. However, total prescriptions for TWYNEO and EPSOLAY declined by 23% and 14% respectively. R&D expenses decreased to $5.3M, contributing to a reduced net loss of $6.3M compared to $10.7M in Q1 2023.